Activity Title: SBS 2016 Virtual Symposium: Advances in Psoriasis Therapy
Activity Format: Virtual Symposium
Program Description:
Psoriasis affects 7.5 million people in the United States and is associated with psychological, arthritic, and cutaneous morbidities, creating a significant quality of life burden on those affected. During this virtual symposium recorded at the 2016 SBS, distinguished faculty will highlight current and emerging therapies for psoriasis as well as provide expert commentary to help answer to your questions.
Intended Audience:
This activity is designed for physicians, physician assistants, and other allied health professionals who manage patients with psoriasis.
Estimated Time to Complete: 1 Hour
Release Date: July 29, 2016
Expiration Date: July 29, 2017
Credit Type(s) Available: ACCME
Maximum Credits: 1 AMA PRA Category 1 Credit(s)TM
Provided By: 
CME Credit provided by AKH Inc., Advancing Knowledge in Healthcare
Commercial Supporter:
The SBS 2016 Virtual Symposium: Advances in Psoriasis Therapy is supported by an educational grant from Pfizer Inc.
Purpose Statement:
To improve patient outcomes through early identification and intervention strategies for patients with, or at risk of developing, diabetes and cardiovascular disease.
Intended Audience:
This activity is designed for physicians, physician assistants, and other allied health professionals who manage patients with psoriasis.
Educational Objectives:
Upon completion of the educational activity, participants should be able to:
- Identify and assess current therapies, their efficacy and safety and their role in treating psoriasis
- Review existing clinical trials and identify emerging therapeutic agents on the horizon
- Discuss the solutions to common therapeutic challenges physicians face in the treatment of psoriasis
Faculty Information:
David Pariser, MD
- Professor, Dermatology
- Eastern Virginia Medical School
- Norfolk, VA
Disclosures:
Advisory Board: Pfizer Inc.
Consultant: Bickel Biotechnology, Biofronera AG, Celgene Corporation, Dermira Inc., DUSA Pharmaceuticals, Inc., LEO Pharmaceuticals, Novartis, Procter & Gamble, Valeant Pharmaceuticals International, Inc.
Contracted Research: Abbott Laboratories, Inc., Amgen, Bickel Biotechnology, Celgene Corporation, Eli Lilly and Company, LEO Pharmaceuticals, Novartis, Novo, Ortho Dermatologics, Peplin Limited, Pfizer Inc., Photocure ASA, Stiefel Laboratories, Valeant Pharmaceuticals International, Inc.
Neal Bhatia, MD
- Director of Clinical Dermatology
- Therapeutics Clinical Research
- San Diego, CA
Disclosures:
Consultant, Contracted Research & Speakers Bureau: ACTAVIS, Allergan, Inc., Anacor Pharmaceuticals, Inc., Aqua Pharmaceuticals, Bayer Healthcare Pharmaceuticals, Biofrontera, Dermira Inc., DUSA Pharmaceuticals, Inc., Exeltis, Ferndale Pharmaceuticals Ltd, Galderma Laboratories, L.P., Intraderm, La Roche Posay, LEO Pharmaceuticals, Merz Pharma, Nerium, Novartis, PharmaDerm, Promius Pharma, LLC., Regeneron Pharmaceuticals, Inc., Sanofi-aventis, Valeant Pharmaceuticals International, Inc.
Mark Lebwohl, MD
- Professor & Chairman, Department of Dermatology
- Icahn School of Medicine at Mount Sinai
- New York, NY
Disclosures:
Dr Lewohl discloses no financial relationships with pharmaceutical or medical product manufacturers.
Leon Kircik, MD
- Associate Clinical Professor
- Mount Sinai Medical Center
- Louisville, KY
Disclosures:
Advisory Board: Aclaris, Allergan, Inc., Anacor Pharmaceuticals, Biogen-Idec, Colbar, Celgene, Connetics Corporation, EOS, Ferndale Laboratories, Inc., Galderma Laboratories, LP, Genentech, Inc., Intendis, Innocutis, Johnson & Johnson, Nano Bio, OrthoNeutrogena, Promius, Quinnova, SkinMedica, Inc., Stiefel Laboratories, Inc., Valeant Pharmaceuticals Intl, Warner-Chilcott
Consultant: Allergan, Inc., Amgen, Inc., Anacor Pharmaceuticals, Colbar, CollaGenex, Connetics Corporation, Galderma Laboratories, LP, Genentech, Inc., Intendis, Johnson & Johnson Laboratory Skin Care Inc., LEO Pharmaceuticals, Medical International Technologies, Merck, Merz, Novartis AG, OrthoNeutrogena, Promius, PuraCap, SkinMedica, Inc., Stiefel Laboratories, Inc., Taro, UCB, Valeant Pharmaceuticals International, Inc., ZAGE
Contracted Research: Acambis, Allergan, Inc., Amgen, Inc., Anacor Pharmaceuticals, Astellas Pharma US, Inc., Asubio, Berlex Laboratories (Bayer HealthCare Pharmaceuticals), Biolife, Biopelle, Boehringer-Ingleheim, Breckinridge Pharma, Celgene, Centocor, Inc., CollaGenex, Combinatrix, Connetics Corporation, Coria, Dermira, Dow Pharmaceutical Sciences, Inc., Dusa, Eli Lilly, Ferndale Laboratories, Inc., Galderma Laboratories, LP, Genentech, Inc., GlaxoSmithKline, PLC, Health Point, LTD, Idera, Intendis, Johnson & Johnson, LEO Pharmaceuticals, L'Oreal, 3M, Maruho, Merck, Medicis Pharmaceutical Corp., Nano Bio, Novartis AG, Noven Pharmaceuticals, Nucryst Pharmaceuticals Corp, Obagi, Onset, OrthoNeutrogena, Promius, QLT, Inc, PharmaDerm, Pfizer, Quinnova, Quatrix, SkinMedica, Inc., Stiefel Laboratories, Inc., TolerRx, UCB, Valeant Pharmaceuticals International, Inc., Warner-Chilcott, XenoPort
Speakers Bureau: Abbott Laboratories, Allergan, Inc., Amgen, Inc., Assos Pharma, Astellas Pharma US, Inc., CollaGenex, Connetics Corporation, Dermik Laboratories, Embil Pharmaceuticals, Galderma Laboratories, LP, Genentech, Inc., Innocutis, Innovail, Johnson & Johnson, LEO Pharmaceuticals, L'Oreal, 3M, Onset, OrthoNeutrogena, PediaPharma, PharmaDerm, Serono (Merck Serono International SA), SkinMedica, Inc., Stiefel Laboratories, Inc., Triax, UCB, Valeant Pharmaceuticals International, Inc., Warner-Chilcott
Disclosure Declaration:
It is the policy of AKH Inc. and The Skin Disease Research and Education Foundation, Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. AKH Inc. & The Skin Disease Research and Education Foundation, Inc. staff, planners and reviewers have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. and The Skin Disease Research and Education Foundation, Inc. specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.
Accreditation
Physician Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and The Skin Disease Research and Education Foundation, Inc. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistants Credit
NCCPA accepts AMA PRA Category 1 Credit(s)TM from organizations accredited by ACCME.
Instructions:
Statements of credit will be awarded based on the participant reviewing the entire presentation, scoring a 70% on the post test, and completing and submitting an activity evaluation. A statement of credit will be available upon completion of an online evaluation/claimed credit form. You must participate in the entire activity to receive credit. If you have questions about this CME activity, please contact AKH Inc. at tbrignoni@akhcme.com.
Hardware and Software Requirements:
This online activity must be viewed with the latest version of Chrome, Firefox or Internet Explorer. If you do not have these browsers, you can download Chrome here, Firefox here and Internet Explorer here. Optimal viewing requires a broadband connection of at least 3 Mbps and a 1 GHz processor with 1 GB RAM.
